WO2009047613A2 - An improved process for the preparation of tadalafil intermediate - Google Patents

An improved process for the preparation of tadalafil intermediate Download PDF

Info

Publication number
WO2009047613A2
WO2009047613A2 PCT/IB2008/002642 IB2008002642W WO2009047613A2 WO 2009047613 A2 WO2009047613 A2 WO 2009047613A2 IB 2008002642 W IB2008002642 W IB 2008002642W WO 2009047613 A2 WO2009047613 A2 WO 2009047613A2
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
peg
tadalafil
process according
glycol
Prior art date
Application number
PCT/IB2008/002642
Other languages
French (fr)
Other versions
WO2009047613A3 (en
Inventor
Vijayabaskar Veerappan
Susi Swaminathan
Rao Siripragada Mahender
Original Assignee
Orchid Chemicals & Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals & Pharmaceuticals Limited filed Critical Orchid Chemicals & Pharmaceuticals Limited
Publication of WO2009047613A2 publication Critical patent/WO2009047613A2/en
Publication of WO2009047613A3 publication Critical patent/WO2009047613A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Definitions

  • the present invention relates to an improved process for the preparation of compound of formula III, which is an important intermediate in the preparation of Tadalafil.
  • Tadalafil is pyrazino(6R, 12aR)-2,3,6,7, 12, 12a- hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',r:6,l]pyrido[3,4- b]indole-l,4-dione. It is marketed in the brand name of CIALIS for oral treatment for erectile dysfunction. Tadalafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It is represented by the following formula I. 0
  • Tadalafil (lR,3R)Methyl-l,2,3,4-tetrahydro-l-(3,4-methylenedioxyphenyl)-9H- pyrido[3,4-b]indole-3-carboxylate of formula III is a key intermediate in the preparation of Tadalafil.
  • Tadalafil was first reported in US patent No. 5,859,006; this patent describes the preparation of this key intermediate by reacting Tryptophan methyl ester of formula II or its acid addition salt with piperonal by using dichloromethane/toluene as a solvent and in the presence of trifluoroacetic acid.
  • This patent also describes the process for preparation of Tadalafil as shown in the below scheme:
  • US patent 7,223,863 discloses a process for the preparation of Tadalafil comprising a step of reacting an acid addition salt of D-Tryptophan methyl ester with piperonal in the presence of high boiling solvent wherein high boiling solvent is selected from N, N-Dimethyl acetamide, Dimethyl sulfoxide, N,N-dimethyl formamide, N-methyl pyrrolidine or mixture thereof and in the presence of dehydrating agent.
  • US2006/0276652 discloses a process for preparing compound of the formula III comprising combining D-Tryptophan methyl ester or a salt thereof and piperonal with at least one organic reaction solvent selected from the group consisting of alky! esters of lower carboxylic acids and aromatic hydrocarbons.
  • US2006/0004203 discloses a process to obtain ( 1R,3 R)M ethyl- 1, 2,3,4- tetrahydro-l-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate by reacting the D-tryptophan methyl ester hydrochloride with piperonal in refluxing isopropyl alcohol.
  • the main objective of the present invention is to provide a facile diastereoselective process for the preparation of tadalafil intermediate of formula III.
  • Another objective of the present invention is to provide a process for the preparation of Tadalafil, which would be easy to implement on commercial scale and will be economically viable.
  • the present invention provides a process for the preparation of (I R ⁇ F ⁇ Methyl- l ⁇ S ⁇ -tetrahydro-l- ⁇ -inethylenedioxyphenyO ⁇ H-pyridoIl ⁇ -bjindole- ⁇ - carboxylate of formula III, which comprises reacting the compound of formula II with piperonal in a mixture of aromatic hydrocarbon solvent and a glycol.
  • D-tryptophancmethyl ester - hydrochloride is reacted with piperonal in a mixture of aromatic solvent and glycol to obtain (lR,3R)Methyl-l,2,3,4-tetrahydro-l-(3,4-methylenedioxyphenyl) ⁇ 9H- pyrido[3,4-b]indole-3-carboxylate.
  • the glycol is preferably polyethylene glycol, which is selected from PEG 200, PEG 300, PEG 400, PEG 600. PEG 100, etc. more preferably PEG 400.
  • the aromatic hydrocarbon solvent is selected from group consisting of toluene, benzene, xylene or mixtures thereof, preferably toluene.

Abstract

The present invention relates to an improved process for the preparation of Tadalafil intermediate (1R,3R)Methyl-1,2,3,4-tetrahydro-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate of formula III comprising a modified Pictet-Spengler reaction between the compound of formula II and piperonal in a mixture of aromatic hydrocarbon solvent and a glycol.

Description

ANIMPROVED PROCESS FORTHE PREPARATION OF TADALAFIL
INTERMEDIATE
Field of the invention
The present invention relates to an improved process for the preparation of compound of formula III, which is an important intermediate in the preparation of Tadalafil.
Figure imgf000002_0001
Background of the invention
The chemical name of Tadalafil is pyrazino(6R, 12aR)-2,3,6,7, 12, 12a- hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',r:6,l]pyrido[3,4- b]indole-l,4-dione. It is marketed in the brand name of CIALIS for oral treatment for erectile dysfunction. Tadalafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It is represented by the following formula I. 0
Figure imgf000002_0002
(lR,3R)Methyl-l,2,3,4-tetrahydro-l-(3,4-methylenedioxyphenyl)-9H- pyrido[3,4-b]indole-3-carboxylate of formula III is a key intermediate in the preparation of Tadalafil. Tadalafil was first reported in US patent No. 5,859,006; this patent describes the preparation of this key intermediate by reacting Tryptophan methyl ester of formula II or its acid addition salt with piperonal by using dichloromethane/toluene as a solvent and in the presence of trifluoroacetic acid. This patent also describes the process for preparation of Tadalafil as shown in the below scheme:
Figure imgf000003_0001
US patent 7,223,863 discloses a process for the preparation of Tadalafil comprising a step of reacting an acid addition salt of D-Tryptophan methyl ester with piperonal in the presence of high boiling solvent wherein high boiling solvent is selected from N, N-Dimethyl acetamide, Dimethyl sulfoxide, N,N-dimethyl formamide, N-methyl pyrrolidine or mixture thereof and in the presence of dehydrating agent.
US2006/0276652 discloses a process for preparing compound of the formula III comprising combining D-Tryptophan methyl ester or a salt thereof and piperonal with at least one organic reaction solvent selected from the group consisting of alky! esters of lower carboxylic acids and aromatic hydrocarbons.
US2006/0004203 discloses a process to obtain ( 1R,3 R)M ethyl- 1, 2,3,4- tetrahydro-l-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate by reacting the D-tryptophan methyl ester hydrochloride with piperonal in refluxing isopropyl alcohol.
US patent 6,911,542 discloses that a D-Tryptophan methyl ester hydrochloride is suspended in acetic acid, water then piperonal to form tadalafil intermediate of formula III.
Most of the prior art processes discussed above have the disadvantages of a long cycle time, a low yield of the desired cis-diastereomer and use of corrosive trifluoroacetic acid. Therefore, there was a long felt need to develop such a process, which can obviate the problems associated with the prior art processes.
Object of the invention
The main objective of the present invention is to provide a facile diastereoselective process for the preparation of tadalafil intermediate of formula III.
Another objective of the present invention is to provide a process for the preparation of Tadalafil, which would be easy to implement on commercial scale and will be economically viable.
Summary of the invention
The present invention provides a process for the preparation of (I R^F^Methyl- l^S^-tetrahydro-l-β^-inethylenedioxyphenyO^H-pyridoIl^-bjindole-θ- carboxylate of formula III, which comprises reacting the compound of formula II with piperonal in a mixture of aromatic hydrocarbon solvent and a glycol.
Figure imgf000004_0001
III Detailed description of the invention
Accordingly, the process of the present invention overcomes the above discussed problems associated with prior art and provides the following advantages:
1. Exclusive formation of cis-isomer
2. Reaction time was reduced more than 10 fold
3. Avoiding the use of corrosive trifluoroacetic acid
In an embodiment of the present invention D-tryptophancmethyl ester - hydrochloride is reacted with piperonal in a mixture of aromatic solvent and glycol to obtain (lR,3R)Methyl-l,2,3,4-tetrahydro-l-(3,4-methylenedioxyphenyl)~9H- pyrido[3,4-b]indole-3-carboxylate.
In another embodiment of the present invention, the glycol is preferably polyethylene glycol, which is selected from PEG 200, PEG 300, PEG 400, PEG 600. PEG 100, etc. more preferably PEG 400.
In another embodiment of the present invention, the aromatic hydrocarbon solvent is selected from group consisting of toluene, benzene, xylene or mixtures thereof, preferably toluene.
The obtained (lR,3R)Methyl-l,2,3,4-tetrahydro-l -(3,4-methylenedioxyphenyl)-
9H-pyrido[3,4-b]indole-3-carboxylate is reacted with a chlorinating agent in a suitable solvent to get (lR,3R)-Methyll,2,3,4-tetrahydro-2-chloroacetyl-(3,4-
" rriethylenedioxyphenyl)-9H-pyrido[3,4 -b]indole-3-carboxylate, which is further treated with primary amine to obtain Tadalafil.
Alternatively, a person skilled in the art can use further (lR,3R.)Methyl~ 1,2,3,4- tetrahydro-l-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate to obtain Tadalafil as per the process available in prior art.
The starting materials used in the invention are either commercially available or can be made by the person skilled in the art according to the process available in prior art. The invention is further illustrated by the following examples, which should not be construed to limit the scope of the invention in anyway.
Example(l)
Preparation of (lR,3R)Methyl-l,2,3,4-tetrahydro-l-(3,4-methylenedioxyphenyl)- 9H-pyrido[3,4-b]indoIe-3-carboxylate (III)
D-Tryptophan methyl ester hydrochloride (100 g), 750 mL of toluene, 250 ml PEG 400 and 64.41 g piperonal were taken in 3 L RBF and stirred the contents at room temperature. The mixture was heated to reflux azeotropically at 100-1100C. After completion of the reaction, the reaction mixture was cooled to 30-350C. To the above reaction mixture 2 L of water followed by 1000ml of ethyl acetate was added with stirring and basified to pH 7.5 - 8.5 by using sodium bicarbonate solution. To this mixture ethyl acetate was added with stirring and the organic layer was separated out and concentrated under vacuum at 600C. To residue To residue isopropyl ether was added. The obtained solid was filtered and washed with isopropyl ether. The solid material was dried under vacuum at 50-550C.
Yield: 80 - 9O g.
Example (2)
(lR,3R)-MethyIl,2,3,4-tetrahydro-2-chloroacetyI-(3,4-methyIenedioxyphenyl)-9H- pyrido[3,4 -b]indole~3-carboxylate (IV)
To compound of formula (III) (100 g) in 2.5 L dichloromethane, triethylamine (79.65 mL) and chloroacetyl chloride (31.2 'mL) were added at 0-50C. After completion of the reaction the reaction mixture was quenched with water. The organic layer was separated out and washed with saturated sodium bicarbonate solution twice followed by water. The organic layer was concentrated up to the residual volume of 2 equivalents with respect to the starting material. Isopropyl alcohol was added to this reaction mass and stirred for 30 minutes. The obtained yellow solid was washed with isopropyl alcohol, filtered and dried at 50 - 600C. Yield: 80.0 g. Example (3) Preparation of Tadalafil (I)
To compound of formula (IV) (100 g) in 1 L of isopropyl alcohol, a solution of methylamine in methanol (25 - 29%; 200 ml) was added at 30 - 35°C. The reaction mass was heated to 50— 55°C till the completion of reaction. The reaction mass was cooled the to 30 — 35°C. The obtained white precipitate was filtered and washed with IPA. The wet cake was dried under vacuum at 60 - 65°C. Yield: 8O g.

Claims

We claim:
1. An improved process for the preparation of (lR,3R)Methyl-l,2,3,4-tetrahydro- l-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate of formula III, which comprises reacting the compound of formula II with piperonal in a mixture of aromatic hydrocarbon solvent and a glycol.
Figure imgf000008_0001
2. A process according to claim 1, wherein the aromatic hydrocarbon solvent is selected from group consists of toluene, benzene, xylene or mixtures thereof.
3. A process according to claim 1, wherein the aromatic hydrocarbon solvent is toluene.
4. A process according to claim 1, wherein the glycol is selected from polyethylene glycols.
5. A process according to claim 1, wherein the polyethylene glycol is selected from PEG 200, PEG 300, PEG 400, PEG 600 and PEG 100.
6. A process according to claim 1, wherein the glycol is PEG 400.
7. A process according to claim 1, which is used further for the preparation of tadalafil.
PCT/IB2008/002642 2007-10-08 2008-10-07 An improved process for the preparation of tadalafil intermediate WO2009047613A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2261/CHE/2007 2007-10-08
IN2261CH2007 2007-10-08

Publications (2)

Publication Number Publication Date
WO2009047613A2 true WO2009047613A2 (en) 2009-04-16
WO2009047613A3 WO2009047613A3 (en) 2009-09-03

Family

ID=40549657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002642 WO2009047613A2 (en) 2007-10-08 2008-10-07 An improved process for the preparation of tadalafil intermediate

Country Status (1)

Country Link
WO (1) WO2009047613A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107549A1 (en) 2011-02-10 2012-08-16 Interquim, S.A. PROCESS FOR OBTAINING COMPOUNDS DERIVED FROM TETRAHYDRO-ß-CARBOLINE
CN106977516A (en) * 2017-03-02 2017-07-25 山东裕欣药业有限公司 A kind of preparation method of Tadalafei

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107549A1 (en) 2011-02-10 2012-08-16 Interquim, S.A. PROCESS FOR OBTAINING COMPOUNDS DERIVED FROM TETRAHYDRO-ß-CARBOLINE
US8829023B2 (en) 2011-02-10 2014-09-09 Interquim, S.A. Process for obtaining compounds derived from tetrahydro-β-carboline
CN106977516A (en) * 2017-03-02 2017-07-25 山东裕欣药业有限公司 A kind of preparation method of Tadalafei
CN106977516B (en) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 A kind of preparation method of Tadalafei

Also Published As

Publication number Publication date
WO2009047613A3 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
AU2019287460B2 (en) Substituted heterocycle fused gamma-carbolines synthesis
AU680320B2 (en) Morpholine derivatives as dopamine receptor subtype ligands
US10336753B2 (en) Process for the preparation of apixaban and intermediates thereof
CN103772384A (en) Preparation method of tadalafil
JP2015519387A (en) Novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted by heterocycles as RS virus antiviral agents
EP1812435A2 (en) Preparation of tadalafil intermediates
WO2010092489A1 (en) Derivatives of azaindoles as inhibitors of protein kinases abl and src
WO1998023592A1 (en) Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient
WO2007052283A1 (en) An improved process for preparing tadalafil and its intermediate
CA2719526A1 (en) Conversion of tryptophan into .beta.-carboline derivatives
JP2021098744A (en) Method for producing novel 4-benzazonine derivative
WO2009047613A2 (en) An improved process for the preparation of tadalafil intermediate
BR112021011854A2 (en) SYNTHESIS OF SUBSTITUTED FUSED HETEROCYCLIC GAMMA-CARBOLINES
WO2010049500A2 (en) A process for the preparation of tadalafil.
US20100130740A1 (en) Process for preparation of risperidone
TW319766B (en)
JP2011522042A (en) Method for producing tadalafil
RU2795581C2 (en) Synthesis of substituted gamma-carbolines condensed with a heterocycle
EP2170880A2 (en) A process for the preparation of intermediates of tetracyclic compounds
JPH09508098A (en) Novel quinolone derivative and method for producing the same
ES2597976B1 (en) METHOD FOR THE PREPARATION OF ACID 1-CICLOPROPIL-6-FLUORO-1,4-DIHIDRO-8-METÓXI-7 - [(4AS, 7AS) -OCTAHIDRO-6H-PIRROLO [3,4-B] PIRIDIN-6-IL ] -] -4-OXO-3- CHINOLINCARBOXYL
WO2011074017A1 (en) A novel process for the preparation of paliperidone
SI26182A (en) Process for the preparation of upadacitinib and its crystalline salts
WO2008053324A1 (en) An improved process for the preparation of gemifloxacin mesylate
KR101476777B1 (en) The new process for the preparation of Paliperidone intermediates (2,4-Difluorophenyl)-piperidinyl-methanone hydrochloride

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837582

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08837582

Country of ref document: EP

Kind code of ref document: A2